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Background: Several large, rare chromosomal copy number variants (CNVs) have recently been shown to
increase risk for schizophrenia and other neuropsychiatric disorders including autism, ADHD, learning dif-
ﬁculties and epilepsy.
Aims: We wanted to examine the frequencies of these schizophrenia-associated variants in a large sample
of individuals with non-psychiatric illnesses to better understand the robustness and speciﬁcity of the
association with schizophrenia.
Methods: We used Affymetrix 500K microarray data from 10,259 individuals from the UK Wellcome Trust
Case Control Consortium (WTCCC) who are affected with six non-psychiatric disorders (coronary artery
disease, Crohn's disease, hypertension, rheumatoid arthritis, types 1 and 2 diabetes) to establish the fre-
quencies of nine CNV loci strongly implicated in schizophrenia, and compared them with the previous
ﬁndings.
Results: Deletions at 1q21.1, 3q29, 15q11.2, 15q13.1 and 22q11.2 (VCFS region), and duplications at 16p11.2
were found signiﬁcantly more often in schizophrenia cases, compared with the WTCCC reference set. Deletions
at 17p12 and 17q12, were alsomore common in schizophrenia cases but not signiﬁcantly so, while duplications
at 16p13.1 were found at nearly the same rate as in previous schizophrenia samples. The frequencies of CNVs in
the WTCCC non-psychiatric controls at three of the loci (15q11.2, 16p13.1 and 17p12) were signiﬁcantly higher
than those reported in previous control populations.
Conclusions: The evidence for association with schizophrenia is compelling for six rare CNV loci, while the
remaining three require further replication in large studies. Risk at these loci extends to other neurodevelop-
mental disorders but their involvement in common non-psychiatric disorders should also be investigated.© 2011 Elsevier B.V. Open access under CC BY license. 1. Introduction
Schizophrenia has a strong genetic componentwith heritability esti-
mates of up to 80% and ~10-fold elevated recurrence risk in ﬁrst-degree
relatives (Gottesman, 1991; Cardno and Gottesman, 2000). Since 2008,
several speciﬁc copy number variants (CNVs) that represent deletions
or duplications of >1000 bp of DNA, have been shown to increase sus-
ceptibility to schizophrenia as well as other neurodevelopmental disor-
ders (International Schizophrenia Consortium, 2008; Stefansson et al.,
2008; Walsh et al., 2008; Xu et al., 2008; Kirov et al., 2009a, 2009b;
McCarthy et al., 2009; Sebat et al., 2009; Moreno-De-Luca et al., 2010;
Mulle et al., 2010; Levinson et al., 2011). All implicated CNVs are veryhiatric Genetics and Genomics,
iff, CF14 4XN, UK.
mbers: seeAcknowledgements.
 license. rare, occurring in about 1:150 to 1:1000 individuals with schizophrenia,
frequencies about 2 to 10 times higher than in controls. However, be-
cause of their rarity, the frequencies in the general population have
not yet been conﬁdently established and estimated effect sizes could
change substantially if additional CNVs are found in other control popu-
lations. Furthermore, the discovery of most loci depended heavily on
the frequencies found in large control samples from the Icelandic popu-
lation, therefore it is important to evaluate these frequencies in other
large control samples, in order to draw deﬁnitive conclusions. Here
we used data from one of the largest genetic studies, the Wellcome
Trust Case Control Consortium (WTCCC), to examine the frequency of
these schizophrenia-associated loci in over 10,000 people from the UK
population who are affected with non-psychiatric disorders. These sub-
jects have not been used as controls in any previous CNV studies of
schizophrenia and so provide independent estimates of the frequencies
of the CNVs in subjects without neurodevelopmental disorders. These
subjects cannot be strictly described as “controls”. They are not a sample
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variety of common medical disorders. However, if the CNVs we test
increase the risk to develop some of these disorders, this would in
fact make our comparison with schizophrenia more conservative.
We will refer to these individuals as the “WTCCC reference set”.
2. Method
2.1. Subjects
We studied data from 10,259 individuals that passed quality control
ﬁltering. Subjects were ascertained by theWTCCCwith coronary artery
disease (CAD, n=1855), Crohn's disease (CD, n=1450), hypertension
(HT, n=1864), rheumatoid arthritis (RA, n=1374), type 1 diabetes
(T1D, n=1903) and type 2 diabetes (T2D, n=1813). They are of
White European ancestry and live in the UK. Extensive information
about the samples and method of genotyping has been published
previously (Wellcome Trust Case Control Consortium, 2007). The
WTCCC study also includes population controls: people born in one
week in 1958, and individuals from the National Blood Transfusion
Service (NBS). These ~3000 control individuals have been used already
to establish the associations of several CNV loci with schizophrenia
(Kirov et al., 2009a; McCarthy et al., 2009) and are therefore not
included in the current analysis. The 1650 bipolar disorder cases
from the WTCCC study are also excluded from analysis as there is
strong evidence for a degree of genetic overlap between bipolar
disorder and schizophrenia (Lichtenstein et al., 2009). The results
on CNVs in the bipolar disorder patients have been published else-
where (Grozeva et al., 2010).
2.2. Genotyping, CNV detection and CNV quality control
Genotyping was performed with Affymetrix 500K arrays that cover
the genome with ~500,000 single nucleotide polymorphisms (SNPs),
as described previously (Wellcome Trust Case Control Consortium,
2007). The signal intensities at each SNP are used to infer the copy num-
ber state. Deletions and duplications result respectively in lower and
higher signal intensities at SNPs in the affected regions. The pre-CNV
calling normalisation procedure and the CNV-calling methods have
been described elsewhere (Olshen et al., 2004; Price et al., 2005;
Barnes et al., 2008). As is now routine for this type of analysis, sev-
eral quality control (QC) ﬁltering steps were applied. These were
removal of samples in which the raw data were of such poor qual-
ity that they were rejected for SNP analyses, or in which the inten-
sity data was highly variable leading to excessive CNV calling (Kirov et
al., 2009a). One potential bias in copy number analysis could arisewhen
comparing samples derived from cell lines and blood as the process of
generating cell lines can result in structural rearrangements (Wang
et al., 2007). To minimise this effect, additional QC measures were
undertaken: removing very large events (>5 Mb), applying a “wave
correction” during normalisation, and removing CNVs from whole
chromosomes where the median chromosomal intensity was an out-
lier from the distribution, as it was observed that such events were
enriched among DNA from cell-lines, suggesting that these are cell-
line artefacts (Wang et al., 2007). CNV calling and QC ﬁltering mea-
sures were performed at the Wellcome Trust Sanger Institute and
subsequently the data were made publicly available.
Previously we performed similar CNV analyses on other pheno-
types from the WTCCC dataset (schizophrenia, n=471, bipolar disor-
der, n=1697, and controls, n=2806) (Kirov et al., 2009a; Grozeva et
al., 2010). All these sample sets were genotyped in the same pipeline
alongwith CAD, CD, RA, HT, T1D and T2D (Wellcome Trust Case Control
Consortium, 2007; O'Donovan et al., 2008a). This work allowed us to
compare the CNV calling performed in house (Kirov et al., 2009a;
Grozeva et al., 2010), with that performed independently by the
WTCCC. Agreement between the calls for these large CNVs was 100%(35 schizophrenia-associated CNVs called by both teams). Thus we
can conclude that we are not introducing bias by analysing CNVs called
at different sites by different analytical methods. This conclusion is
in agreement with the widely accepted view that CNVs larger than
500,000 bp are reliably called with any high-density microarrays.
All CNVs discussed in this report are >600,000 bp long and covered
with between 25 to several hundred probes on the arrays, allowing a
reliable comparison with the previous studies.
All chromosomal positions presented in this paper are according
to NCBI Build 36 (hg18), March 2006 of the UCSC Genome Browser.
2.3. Analysed loci
We chose to analyse loci that have received replicated evidence
from multiple large studies (International Schizophrenia Consortium,
2008; Stefansson et al., 2008; Kirov et al., 2009a, 2009b; McCarthy et
al., 2009; Moreno-De-Luca et al., 2010; Mulle et al., 2010; Ingason et
al., 2011; Levinson et al., 2011). The vast majority of samples were of
white European ancestry, with the exception of 1274 schizophrenia
cases and 963 controls of African American origin who were included
in the study of Levinson and colleagues (Levinson et al., 2011). Details
of the previous evidence for each locus are presented in the Results
and Discussion sections and Table 1. We compared the frequency of
CNVs in the WTCCC reference set with that in the schizophrenia
cases taken from the largest published studies or reviews (for 1q21.1,
15q13.3, 16p11.2, 17p12, 17q12 and 22q11.2) or from combined data
from studies that had at least 1000 cases and 1000 controls (for 3q29,
15q11.2 and 16p13.1), excluding any individuals who had taken
part in more than one of these studies (International Schizophrenia
Consortium, 2008; Kirov et al., 2009a; McCarthy et al., 2009; Moreno-
De-Luca et al., 2010; Mulle et al., 2010; Ingason et al., 2011; Levinson
et al., 2011). Deletions at the NRXN1 gene, also implicated as a risk
factor for schizophrenia, (Kirov et al., 2009b) or at other individual
genes implicated recently (Levinson et al., 2011) were not analysed
as the CNVs affecting them are usually much smaller than 500,000 bp
and can be missed with the lower-resolution array used in the current
study. We did not attempt a formal meta-analysis, which would not be
appropriate, as the new set of studied individuals does not include peo-
ple affectedwith schizophrenia. Therefore, for uniformity, we present all
resultswith a pooled analysis of all available individuals performedwith
the Fisher's Exact Test. Formal meta-analyses results are available for
some of the published loci and the odds ratios (OR) and p-values
reported by these two statistical methods in the previous studies are
very similar (Levinson et al., 2011).
3. Results
Results are presented in Table 1. We present the frequency of the
CNVs in schizophrenia cases and controls (columns 5 and 2) derived
from the appropriate reviews (cited in the last column). Where a
review of the majority of the data was not available (in the case of
3q29, 15q11.2 and 16p13.1), we combined the results from the
largest published reports (listed in the last column), after excluding
samples used in more than one study, where appropriate. The stud-
ies in Table 1 comprise the bulk of available high-quality CNV data,
with >5000 individuals with schizophrenia and >37,000 controls
for each locus. Despite the smaller size of the WTCCC reference
set, compared to the size of the previous control populations, six
out of the nine CNVs received statistically signiﬁcant support for
association with schizophrenia. Details on each locus are presented
in the Discussion. The frequencies of three CNVs were signiﬁcantly
higher than those reported in previous control populations (15q11.2,
16p13.1 and 17p12, p-values presented in column 4 of Table 1), most
notably for the 16p13.1 duplication, p=0.001, which is also the only
p-value that would survive a Bonferroni correction for multiple testing
of nine independent events (p=0.006).
Table 1
Loci implicated in schizophrenia.
CNV
(position, Mb)a
Rate in previous
controlsc
Rate in WTCCC
reference setc
p-value b: WTCCC vs.
previous controls
Rate in SZ
casesc
p-value b: SZ vs. previous
controls OR (95%CI)
p-value b: SZ vs. WTCCC
reference set OR (95%CI)
Publication
1q21.1 del 10/47, 321 1/10, 259 0.78 20/11,392 2.2×10−8 3.2×10−5 (Levinson et al., 2011)
(144.9–146.3) (0.021%) (0.01%) (0.18%) 8.3 (3.7–19.9) 18.8 (2.89–749.3)
3q29 del 1/40,941 0/10,259 1 9/9323 2×10−6 0.001 (Mulle et al., 2010; Levinson
et al., 2011)(197.4–198.8) (0.002%) (0%) (0.097%) 39.6 (5.5–1734) (2.2–∞)d
15q11.2 del 120/50,108 40/10,259 0.01 68/11,863 4.13×10−8 0.05 (Kirov et al., 2009a; Levinson
et al., 2011)(20.2–20.8) (0.24%) (0.39%) (0.57%) 2.4 (1.8–3.3) 1.5 (1–2.2)
15q13.3 del 9/45,922 4/10,259 0.4 21/10,887 2.0×10−9 0.001 (Levinson et al., 2011)
(28.7–30.3) (0.02%) (0.039%) (0.19%) 9.9 (4.3–24.4) 5.0 (1.7–19.9)
16p11.2 dup 8/28, 406 4/10,259 0.8 26/8590 7.63×10−11 3.9×10−6 (McCarthy et al., 2009)
(29.5–30.1) (0.028%) (0.039%) (0.3%) 10.8 (4.7–27.6) 7.8 (2.7–30.7)
16p13.1 dup 38/37,595 25/10,259 0.001 20/7075 4.3×10−4 0.65 (ISC, 2008; Ingason et al.,
2011)(15.0–16.2) (0.10%) (0.24%) (0.28%) 2.8 (1.5–4.9) 1.2 (0.6–2.2)
17p12 del 6/38,884 7/10,259 0.02 8/5089 5×10−5 0.11 (Kirov et al., 2009a)
(14.0–15.4) (0.015%) (0.068%) (0.16%) 10.2 (3.1–35.7) 2.3 (0.7–7.5)
17q12 del 0/47,929 2/10,259 0.06 4/6340 2×10−4 0.2 (Moreno-De-Luca et al.,
2010)(31.8–33.3) (0%) (0.02%) (0.06%) (4.9–∞)d 3.2 (0.7–35.8)
22q11.2 del 0/45,361 0/10,259 1 35/11,400 3.8×10−25 3.4×10−10 (Levinson et al., 2011)
(17.4–19.8) (0%) (0%) (0.31%) (35.9–∞)d (8.1–∞)d
a The coordinates (cytogenetic band and position in Mb on the chromosomes according to Build 36) are given in column 1 and exclude ﬂanking low copy repeats.
b All p-values are fromFisher's exact test. Details for each locus are presented in the Discussion.WTCCC reference set denotes the 10,259 individuals with non-psychiatric disorders; SZ:
schizophrenia.
c The rates in each population (columns 2, 3 and 5) are presented as numbers of CNV carriers/numbers of all tested individuals.
d The OR for these CNVs cannot be estimated, as no deletion carriers were found in the control populations, ORs are presented as (lower 95%CI-∞).
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each disease cohort comprising the WTCCC reference set. There are
no statistically signiﬁcant differences in the frequencies of the CNVs
between any cohorts, but this is expected, given the small sample
size of each cohort and the rarity of the CNVs.
4. Discussion
Several large CNVs have previously received strong replicated
support for association with schizophrenia: deletions at 1q21.1
(International Schizophrenia Consortium, 2008; Stefansson et al.,
2008), 2p16.3, affecting the NRXN1 gene (Kirov et al., 2008, 2009b;
Rujescu et al., 2009), 3q29 (Mulle et al., 2010; Levinson et al., 2011),
15q11.2 (Stefansson et al., 2008; Kirov et al., 2009a), 15q13.3
(International Schizophrenia Consortium, 2008; Stefansson et al.,
2008), 17p12 (Kirov et al., 2009a), 17q12 (Moreno-De-Luca et al.,
2010) , 22q11.2 (the Velo-Cardio-Facial Syndrome (VCFS) region)
(Bassett and Chow, 2008; International Schizophrenia Consortium,
2008; Stefansson et al., 2008; Levinson et al., 2011) and duplications
at 16p11.2 (McCarthy et al., 2009) and 16p13.1 (Ingason et al., 2011).
These studies used a total of between ~5000–11,000 cases and
~37,000–50,000 controls, and produced strong statistical support
for association with disease, with p-values of between 4.3×10−4
and 3.8×10−25. The CNVs have very low frequencies in controls,
and further studies are required both to conﬁrm several of theseTable 2
Number of CNVs for the studied loci in the separate cohorts comprising the WTCCC
reference set.
CNV RA
(1374)
CD
(1450)
T1D
(1903)
T2D
(1813)
CAD
(1855)
HT
(1864)
1q21.1 del 0 0 0 0 1 0
3q29 del 0 0 0 0 0 0
15q11.2 del 5 3 8 12 6 6
15q13.3 del 0 0 0 2 2 0
16p11.2 dup 0 0 2 0 1 1
16p13.1 dup 2 6 4 5 4 4
17p12 del 1 1 1 2 1 1
17q12 del 0 1 0 1 0 0
22q11.2 del 0 0 0 0 0 0
The numbers of studied individuals are provided in brackets. None of the subjects
carried more than one of these CNVs.associations and to establish more accurately their frequencies in
patients and in the population of people without neuropsychiatric
illness, thus enabling more accurate estimates of effect sizes of risk.
Although the numbers of controls were much larger than the ones
used in the current study, almost all previous ﬁndings were heavily
supported by data on >30,000 controls from a single country (Iceland),
therefore a comparison with another large sample of controls from
another country appeared to be justiﬁed.
Here we studied a sample of 10,259 individuals from the UK,
affected with several common non-neuropsychiatric disorders. This
dataset allowed us to assess the frequency of these CNVs in an indepen-
dent sample of comparison subjects. These individuals have not been
screened for the presence of schizophrenia or other CNV-related neuro-
developmental disorders. Nevertheless, the prevalence of schizophrenia
is only about 1% in the general population, and therefore the use of
unscreened reference samples is not expected to make an appreciable
difference to the results. Even if 100 of the ~10,000 controls have schizo-
phrenia (~1%), these will not contribute more than two or three CNVs in
total from those listed in Table 1, as their combined frequency in cases is
~2%. Furthermore, the presence of people with psychiatric disorders in
this reference set would only reduce the strength of association be-
tween these CNVs and schizophrenia, therefore the current study
provides a conservative estimate of this association. Another
~3000 control subjects that are part of the WTCCC study have been
used in the identiﬁcation of several of these loci, and are therefore
not included in the current analysis (Kirov et al., 2009a; McCarthy
et al., 2009). The combined burden of the examined loci in Table 1
in these ~3000 controls does not signiﬁcantly differ from that in
the 10,259 non-psychiatric reference group (Yates corrected χ2
p-value=0.92).
Overall six of the loci remain signiﬁcantly more common in the sub-
jects affectedwith schizophrenia, compared to theWTCCC reference set
(1q21.1, 3q29, 15q11.2, 15q13.1, 16p11.2 and 22q11.2). This is despite
the fact that the new comparison sample is ~4 times smaller than
the previously used combined control samples. This provides strong
additional support that these CNVs are true risk factors for schizo-
phrenia. For the remaining three loci (16p13.1, 17p12 and 17q12)
the differences were not statistically signiﬁcant (Table 1, column
7). When we compared the rate of the studied CNVs in the non-
psychiatric WTCCC reference set with the rate in the previous con-
trols (Table 1, column 4) we observed statistically signiﬁcant higher
Table 3
Rate of CNVs in previous studies on schizophrenia and in all control samples (combined
previous controls+WTCCC reference set).
CNV
(position, Mb)
Rate in SZ cases Rate in combined
controls
p-value: SZ vs. combined
controls OR (95%CI)
1q21.1 del 20/11,392 11/57,580 2.9×10−9
(144.9–146.3) (0.18%) (0.02%) 9.2 (4.2–21.3)
3q29 del 9/9323 1/51,200 4.2×10−7
(197.4–198.8) (0.097%) (0.002%) 49.5 (6.9–2168)
15q11.2 del 68/11,863 160/60,367 5.7×10−7
(20.2–20.8) (0.57%) (0.27%) 2.2 (1.6–2.9)
15q13.3 del 21/10,887 13/56,181 2.7×10−9
(28.7–30.3) (0.19%) (0.023%) 8.3 (4–18.2)
16p11.2 dup 26/8590 12/38,665 1.8×10−11
(29.5–30.1) (0.3%) (0.031%) 9.8 (4.8–21.3)
16p13.1 dup 20/7075 63/47,854 0.005
(15.0–16.2) (0.28%) (0.13%) 2.1 (1.2–3.6)
17p12 del 8/5089 13/49,143 0.0004
(14.0–15.4) (0.16%) (0.026%) 5.9 (2.1–15.5)
17q12 del 4/6340 2/58,188 0.001
(31.8–33.3) (0.06%) (0.003%) 18.4 (2.6–203)
22q11.2 del 35/11,400 0/55,620 1.1×10−27
(17.4–19.8) (0.31%) (0%) (44.2–∞)a
a The OR for the 22q11.2 deletion cannot be estimated, as no deletion carriers were
found in controls, but the lower conﬁdence interval of the OR is 44.2.
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16p13.1, and 17p12. This is most notable for the 16p13.1 duplications
(Results), with a frequency of 0.24% among the WTCCC reference
set, almost an identical frequency to that reported for schizophrenia
in previous studies (0.28%). This suggests the possibility the original
ﬁnding might have been a false-positive.
The difference between the control/ reference sets, and the observa-
tions that the rates of CNVs at 16p13.1, 17p12 and 17q12 were not sta-
tistically different between schizophrenia cases and the non-psychiatric
WTCCC reference set suggest that either these CNVs also increase the
risk to develop some of the disorders that comprise theWTCCC sample,
or that the odds ratios in the original studies were inﬂated, or even
false-positives, or that the use of the smaller set of controls here is
underpowered. In Table 2 we present the numbers of the pathogenic
CNVs observed in each disease cohort that comprise the WTCCC ref-
erence set in order to examine if these CNVs also increase the risk to
develop some of the non-psychiatric disorders. Type 2 diabetes cases
had the highest rate of schizophrenia-related CNVs, a cumulative
rate of 1.2%. This is intriguing given strong epidemiological evidence
for an increased rate of several chronic somatic disorders among
patients with schizophrenia, including Diabetes 1 and 2 types, cere-
brovascular disorders and myocardial infarction. The cumulative rate
of these CNVs in the rest of the cohorts ranged from 0.58 to 0.8. It is of
note that the lowest cumulative CNV burden is found for rheumatoid
arthritis (0.58%), as there is evidence of inverse co-morbidity be-
tween schizophrenia and connective tissue disorders, most notably
rheumatoid arthritis (Mors et al., 1999; Laursen et al., 2011). This
raises the intriguing question as to whether CNVs are partially re-
sponsible for this inverse comorbidity; answering this question will
require larger studies of these CNVs in rheumatoid arthritis.
The decrease of the estimated odds ratios for several loci in the
new analysis could be also due to the bias known as the “winner's
curse” (Zollner and Pritchard, 2007). This arises because if it is under-
powered, the ﬁrst study reporting an association tends to be per-
formed on a sample where the odds ratio happens to be inﬂated, as
explained elsewhere (Craddock et al., 2008). Nevertheless, the com-
parisons of the frequencies of these CNVs in cases and in the overall
‘control’ populations (those previously used+the new WTCCC refer-
ence set) remain highly signiﬁcant for each locus, with only minor
ﬂuctuation of the signiﬁcant levels of up to one order of magnitude
(Table 3).
We will now discuss how the current results relate to previous
ﬁndings for each locus.
4.1. 1q21.1 deletion
This 1.4 Mb deletion contains 11 genes and was found to be
associated with schizophrenia in the three largest CNVs surveys
(International Schizophrenia Consortium, 2008; Stefansson et al.,
2008; Levinson et al., 2011). It has also been implicated in develop-
mental delay, dysmorphic features, cardiac abnormalities, and learning
disability (Christiansen et al., 2004; Brunetti-Pierri et al., 2008; Mefford
et al., 2008; O'Donovan et al., 2008b). Our results conﬁrm their extreme
rarity in people who are not affected with neuropsychiatric disorders
and give further support for the association with schizophrenia
(p=3.2×10−5).
4.2. 3q29 deletion
Deletions of 3q29, spanning 1.4 Mb and 21 genes, were ﬁrst reported
to be associated with schizophrenia byMulle et al. (2010). Likemany of
the other schizophrenia associated CNVs, this variant has been also
found to be associated with intellectual disability and autism (Ballif et
al., 2008; Mulle et al., 2010). No deletions were observed in the
WTCCC reference set, providing further support that this is a risk factor
for susceptibility to schizophrenia (p=0.001).4.3. 15q11.2 deletion
The ﬁrst report of an association between the 0.6 Mb deletions at
this locus that span four genes, and schizophrenia was made by
Stefansson et al. (2008). The data in Table 1 for this locus were com-
bined from the Kirov et al. review and the study by Levinson et al.
(Kirov et al., 2009a; Levinson et al., 2011). The rate of this deletion
in the newWTCCC subjects is 0.39%, a higher rate than in the previous
controls (0.24%), but lower than among cases (0.57%), thus providing
independent support for the association (p=0.05). Other studies give
further support for the role of this CNV in neuropsychiatric disorders
(Doornbos et al., 2009; Mefford et al., 2009), with the highest rate of
this deletion (1%) found in patientswith idiopathic generalised epilepsy
(deKovel et al., 2010). The prevalence and phenotypicmanifestations of
this CNV need further investigation.
4.4. 15q13.3 deletion
The association with schizophrenia of this 1.5 Mb deletion that
spans seven genes, is supported by the three largest studies in schizo-
phrenia (The Molecular Genetics of Schizophrenia (Levinson et al.,
2011), the International Schizophrenia Consortium (International
Schizophrenia Consortium, 2008) and Stefansson et al. (2008)) as
reviewed by Levinson et al. (2011). The rate of the 15q13.3 deletion
in the newWTCCC reference set is very low at 1:2500, conﬁrming the
role of this CNV in schizophrenia (p=0.001). Similar to other loci
implicated in schizophrenia, this deletion is associated with other
neuropsychiatric phenotypes. Sharp and colleagues described a syn-
drome presenting with mental retardation, seizures and variable facial
dysmorphic features (Sharp et al., 2008). The deletion is found at ~1%
among patients with idiopathic generalised epilepsy (Dibbens et al.,
2009; Helbig et al., 2009) and at 0.17% among individuals suffering
with mental retardation, developmental delay and autism (Miller et
al., 2009).
4.5. 16p11.2 duplication
A largemeta-analysis observed this 0.6 Mbduplication containing26
genes at a rate of ~1:300 schizophrenia patients and ~1:3500 controls
(McCarthy et al., 2009). The rate in the new WTCCC reference set
(~1:2500) is very similar to that among previous controls, and pro-
vides strong support for the association with schizophrenia
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while the reciprocal deletion of this locus is associated with autism
and developmental delay (McCarthy et al., 2009). The reciprocal
deletion is recognised as one of the most common molecular risk
factor for autism, but it does not appear to be a risk factor for
schizophrenia (McCarthy et al., 2009). In the current study, four
WTCCC reference subjects carried the deletion.
4.6. 16p13.1 duplication
This 1.2 Mb duplication spanning eight genes was ﬁrst implicated
as a risk factor for autism (Ullmann et al., 2007) and mental retarda-
tion (Mefford et al., 2009). Ingason et al. observed a 3-fold excess of
duplications and deletions in cases with schizophrenia compared to
controls (Ingason et al., 2011). Table 1 combines their results with
those from the International Schizophrenia Consortium (2008), result-
ing in a 3-fold increase in cases: ~1:350 patients carry the duplication,
vs. ~1:1000 controls. In the current study we found a high rate of this
duplication in control subjects (~1:400), which is quite close to
that observed in schizophrenia cases (~1:350). As noted above, this
at least raises the question whether the ﬁrst observation was a
false-positive result. The carriers in the present study did not come
predominantly from a single phenotype that can explain the in-
creased rate (Table 2). It is therefore not clear why there is such a
strong difference between the rate in the WTCCC reference set and
that in previous controls (0.24% vs. 0.1%, Fisher's exact test
p=0.001). One possibility is that the lower rate in the previous ﬁnd-
ings was due to exclusion of subjects that had known neuropsychiat-
ric disorders in the study by Ingason et al. (2011), as further studies
also support the pathogenic role of this CNV in such disorders. Thus,
Mefford et al. detected duplications in 1.1% of individuals with unex-
plained intellectual disability (Mefford et al., 2009), de Kovel et al.
found deletions at this locus in 6/1234 epilepsy patients (0.5%) and
in 2/3022 controls (0.07%), OR=7.4 (de Kovel et al., 2010), and Wil-
liams et al. found an excess of duplications (0.84%) in attention-
deﬁcit hyperactivity disorder cases (Williams et al., 2010). Perhaps
evenmore intriguing is the strong association of this CNVwith aortic
dissections (Kuang et al., 2011). The duplication is under strong se-
lection pressure, indicating that it is pathogenic (Rees et al., 2011).
Further studies on cases, controls and other phenotypes are needed
to resolve the role of this CNV that appears to be pathogenic in gen-
eral, but not clearly associated with schizophrenia.
4.7. 17p12 deletion
This 1.4 Mb deletion causes the neurological disorder hereditary
neuropathy with pressure palsies (HNPP, MIM #162500) (Chance et
al., 1993), while the reciprocal duplication causes Charcot–Marie–
Tooth disease Type 1A (CMT1A, MIM #118220) (Lupski et al., 1991).
The deletion was found to be 10 times more common in schizophrenia
cases than in controls (0.16% vs. 0.015%, p=5×10−5) (Kirov et al.,
2009a). These results are based on a smaller sample size than any of
the other loci in Table 1. The current study ﬁnds a relatively high rate of
this deletion in the WTCCC reference set: 7 out of 10,259 individuals, a
4-fold higher rate than in previous controls (p=0.02). This is still much
lower than the rate in schizophrenia patients, however the new ﬁndings
are not statistically signiﬁcant (p=0.11) and weaken the evidence from
the previous association. The association still remains highly signiﬁcant in
the overall analysis (Table 3).
4.8. 17q12 deletion
Deletions of 1.5 Mb at this region have been associated with
schizophrenia (Moreno-De-Luca et al., 2010), as well as with autism/
neurocognitive impairment (Loirat et al., 2010; Moreno-De-Luca et al.,
2010). One of the 15 geneswithin the locus,HNF1B, has been implicatedin the renal cysts and diabetes (RCAD) syndrome (Bingham and
Hattersley, 2004). This CNV can present also with various medical con-
ditions (macrocephaly, characteristic facial features, genitourinary tract
anomalies, recurrent infections and diabetes) (Moreno-De-Luca et al.,
2010; Nagamani et al., 2010). Interestingly one of the twoWTCCC sub-
jects harbouring this deletion is from the type 2 diabetes cohort. The
current results weaken the evidence for this CNV as a susceptibility
factor for schizophrenia, although it remains signiﬁcant in the com-
bined analysis (Table 3) and should be tested in further studies.
4.9. 22q11.2 deletion
Deletions of 2.4 Mb at this locus constitute a known genomic dis-
order, 22q11.2 Deletion Syndrome, also known as Velo-Cardio-Facial
Syndrome (VCFS) or DiGeorge Syndrome (Shprintzen et al., 1978).
This was the ﬁrst CNV shown to increase the risk for developing psy-
chosis (Murphy et al., 1999). Levinson et al. reported a frequency of
~0.32% among 11,400 schizophrenia cases, while no control with the
full deletion was found in any control samples (Table 1) (Levinson et
al., 2011). No deletions were observed in the WTCCC reference set
either, conﬁrming once again the status of this locus as a highly
penetrant risk factor for schizophrenia (lower conﬁdence interval
for the OR=44.2, p=1.1×10−27) and other neurodevelopmental
disorders.
The current study provides further support for the involvement of
deletions at 1q21.1, 3q29, 15q11.2, 15q13.3, 22q11.2 and duplications
at 16p11.2 as risk factors for schizophrenia. The evidence implicating
deletions at 17p12 and 17q12 and especially duplications at 16p13.1
is weaker and needs further study. All of these loci have also been
shown to increase risk for other neuropsychiatric disorders, indicating
that these rare, large DNA variants are not phenotype-speciﬁc. Further-
more, most carriers of these CNVs do not develop schizophrenia (i.e.
they have a limited penetrance for this disorder of 2–7.4%), with the ex-
ception of the deletion at 22q11.2 that has an estimated penetrance of
55% (Vassos et al., 2010).
An important limitation of our study is that most of these CNVs
cause other medical disorders and therefore could be found among
cohorts recruited for other conditions. This could explain why the
rate in the WTCCC comparison subjects was higher than in previously
analysed controls for several of these loci. While the overall burden of
these CNVs appears to be the same in theWTCCC non-psychiatric refer-
ence set and ~3000 controls (see above), this study has no statistical
power to estimate if any individual non-psychiatric disorder in the
WTCCC has an increased burden of any single CNV locus discussed
here. Judging from the experience in schizophrenia, such associations
have to be tested on >5000 cases from each phenotype.
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